Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond

Gérard, Camille L.; Shum, Benjamin; Nathan, Paul; Turajlic, Samra

doi:10.1016/j.iotech.2023.100386

Cited by 1 publication

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the registered immunoglobulins are amivantamab and tebentafusp. They demonstrate promising results and represent a significant advancement in combating locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 20 insertions in the EGFR gene after treatment with platinum-based chemotherapy, and uveal melanoma (UM) [50,51].…”

Section: Other Approved Bispecific Antibodiesmentioning

confidence: 99%

Double hit — bispecific antibodies in cancer therapy

Bogdanowicz,

Wojas-Krawczyk,

Krzyżanowska

et al. 2024

Oncol Clin Pract

View full text Add to dashboard Cite

Immunotherapy has emerged as a promising strategy for cancer treatment, with bispecific antibodies (BsAbs) demonstrating significant therapeutic potential. BsAbs are biological molecules capable of simultaneously binding to two distinct antigens, allowing the immune response to target cancer cells precisely. However, despite promising results in preclinical studies and early clinical trials, immunotherapy based on these antibodies faces several significant issues that require careful consideration. One of them is the development of therapy resistance, which often leads to a loss of treatment effectiveness. Another challenge is the associated toxicity of immunotherapy. While BsAbs are designed to limit adverse effects, there remains a risk of side effects that can impact the quality of life for patients. Furthermore, it should be noted that the production of BsAbs is burdened with significant costs and involves complex processes, negatively affecting the accessibility of this therapy for the majority of patients. Hence, continuous efforts are necessary to develop more efficient and cost-effective methods for producing these antibodies to enable a broader range of patients to benefit from this innovative therapy.

show abstract

Section: Other Approved Bispecific Antibodiesmentioning

confidence: 99%